5. 進行性核上性麻痺 Progressive supranuclear palsy Clinical trials / Disease details
臨床試験数 : 89 / 薬物数 : 107 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05187546 (ClinicalTrials.gov) | March 10, 2022 | 23/11/2021 | Test-retest Study With [18F]PI-2620 in PSP-RS and NDC | An Open Label, Single Center Study to Evaluate the Safety and Test-retest Characteristics of [18F]PI-2620 as PET Radioligand for Imaging Tau Deposition in the Brains of Patients With Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) Compared to Non-demented Controls (NDC) | Progressive Supranuclear Palsy | Drug: [18F]-PI2620 | Life Molecular Imaging GmbH | NULL | Recruiting | 50 Years | 80 Years | All | 15 | Phase 1 | Germany |
| 2 | NCT03446807 (ClinicalTrials.gov) | December 2021 | 20/2/2018 | Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism | Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism | Parkinson Disease;Multiple System Atrophy;Progressive Supranuclear Palsy | Drug: Droxidopa;Drug: Placebo Oral Tablet | Loma Linda University | H. Lundbeck A/S | Not yet recruiting | 50 Years | N/A | All | 32 | Phase 2 | United States |
| 3 | NCT04937530 (ClinicalTrials.gov) | June 23, 2021 | 16/6/2021 | RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY | A Randomized, Double-blind, Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: RT001;Drug: Placebo | Retrotope, Inc. | NULL | Recruiting | 40 Years | 80 Years | All | 40 | Phase 2 | Germany |
| 4 | EUCTR2020-003911-90-PL (EUCTR) | 07/05/2021 | 20/04/2021 | A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH PROGRESSIVE SUPRANUCLEAR PALSY. | A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH PROGRESSIVE SUPRANUCLEAR PALSY. | Progressive supranuclear palsy (PSP) MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: RT001 Product Code: RT001 INN or Proposed INN: not assigned Other descriptive name: 9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER | Retrotope, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 40 | Phase 2 | Hungary;Slovakia;Poland;Germany | ||
| 5 | EUCTR2020-003911-90-DE (EUCTR) | 31/03/2021 | 30/11/2020 | A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH PROGRESSIVE SUPRANUCLEAR PALSY. | A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH PROGRESSIVE SUPRANUCLEAR PALSY. | Progressive supranuclear palsy (PSP) MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: RT001 Product Code: RT001 INN or Proposed INN: not assigned Other descriptive name: 9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER | Retrotope, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Phase 2 | Hungary;Slovakia;Poland;Germany | ||
| 6 | EUCTR2020-003911-90-SK (EUCTR) | 23/03/2021 | 13/01/2021 | A study to learn how well the drug RT001 works and how safe RT001 is in people who have progressive supranuclear palsy. | A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH PROGRESSIVE SUPRANUCLEAR PALSY. | Progressive supranuclear palsy (PSP) MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: RT001 Product Code: RT001 INN or Proposed INN: not assigned Other descriptive name: 9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER | Retrotope, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 40 | Phase 2 | Hungary;Slovakia;Poland;Germany | ||
| 7 | EUCTR2020-003911-90-HU (EUCTR) | 19/02/2021 | 09/12/2020 | A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH PROGRESSIVE SUPRANUCLEAR PALSY. | A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH PROGRESSIVE SUPRANUCLEAR PALSY. | Progressive supranuclear palsy (PSP) MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: RT001 Product Code: RT001 INN or Proposed INN: not assigned Other descriptive name: 9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER | Retrotope, Inc | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 2 | Hungary;Slovakia;Poland;Germany | ||
| 8 | NCT04539041 (ClinicalTrials.gov) | February 16, 2021 | 25/8/2020 | Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy | A Randomized, Participant, Investigator and Sponsor Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intrathecally Administered NIO752 in Participants With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy (PSP) | Drug: antisense oligonucleotide;Drug: placebo | Novartis Pharmaceuticals | NULL | Recruiting | 40 Years | 75 Years | All | 66 | Phase 1 | United States;Canada;Germany;United Kingdom |
| 9 | NCT04734379 (ClinicalTrials.gov) | January 22, 2021 | 18/1/2021 | Rho Kinase (ROCK) Inhibitor in Tauopathies - 1 | A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients With the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome. | Progressive Supranuclear Palsy;Corticobasal Syndrome | Drug: Fasudil | Woolsey Pharmaceuticals | NULL | Active, not recruiting | 35 Years | 80 Years | All | 15 | Phase 2 | United States |
| 10 | NCT04253132 (ClinicalTrials.gov) | January 1, 2021 | 17/12/2019 | Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks | A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Tolfenamic Acid for the Treatment of Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Tolfenamic Acid;Drug: Placebos | NeuroTau, Inc. | The Cleveland Clinic | Not yet recruiting | 40 Years | 85 Years | All | 24 | Phase 1/Phase 2 | United States |
| 11 | ChiCTR2000041207 | 2021-01-01 | 2020-12-22 | A registered cohort study on progressive supranuclear palsy (PSP) | A registered cohort study on progressive supranuclear palsy (PSP) | progressive supranuclear palsy | Gold Standard:Diagnostic criteria of MDS for progressive supra-nuclear palsy (2017) and the Chinese clinical diagnostic criteria for progressive supra-nuclear palsy (2016).;Index test:The progression of PSP rating scales. Tau protein-related pathological examination (for example, Tau protein content in blood, Tau protein-related detection in cerebrospinal fluid in patients with cognitive impairment, etc.), and brain Tau PET imaging.; | Huashan Hospital, Fudan University | NULL | Recruiting | 40 | 85 | Both | Target condition:100;Difficult condition:0 | China | |
| 12 | NCT04658199 (ClinicalTrials.gov) | November 16, 2020 | 1/12/2020 | A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy | An Open-Label Extension Study to Evaluate the Safety and Tolerability of Long-Term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: UCB0107 (bepranemab) | UCB Biopharma SRL | NULL | Active, not recruiting | 40 Years | N/A | All | 19 | Phase 1 | Belgium;Germany;Spain;United Kingdom |
| 13 | NCT04715750 (ClinicalTrials.gov) | November 12, 2020 | 11/12/2020 | Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity | An Open Label, Single Center Study to Evaluate the Safety and Imaging Characteristics of [18F]PI-2620 as PET Radioligand for Imaging Tau Deposition in the Brains of Patients With Mild to Moderate Alzheimer's Disease (AD) and Patients With Progressive Supranuclear Palsy (PSP) After i.v. Application of [18F]PI-2620 With High and Low Specific Activity | Alzheimer Disease;Progressive Supranuclear Palsy | Drug: [18F]-PI2620 | Life Molecular Imaging GmbH | Life Molecular Imaging SA | Active, not recruiting | 50 Years | 80 Years | All | 10 | Phase 1 | Germany |
| 14 | NCT04008355 (ClinicalTrials.gov) | June 22, 2020 | 18/6/2019 | A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP | A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 on Cerebrospinal Fluid Biomarkers in 36 Patients With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: AZP2006 oral solution;Drug: Placebo oral solution | AlzProtect SAS | NULL | Completed | 40 Years | 80 Years | All | 36 | Phase 2 | France |
| 15 | NCT04185415 (ClinicalTrials.gov) | December 3, 2019 | 2/12/2019 | A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) | A Participant-Blind, Investigator-Blind, Placebo-Controlled, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) | Progressive Supranuclear Palsy | Drug: bepranemab;Drug: Placebo | UCB Biopharma SRL | NULL | Completed | 40 Years | N/A | All | 25 | Phase 1 | Belgium;Germany;Spain;United Kingdom |
| 16 | NCT03924414 (ClinicalTrials.gov) | November 15, 2019 | 2/4/2019 | Trial of Parkinson's And Zoledronic Acid | TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease | Parkinson Disease;Osteoporosis;Parkinsonism;Parkinson's Disease and Parkinsonism;Atypical Parkinsonism;Progressive Supranuclear Palsy;Multiple System Atrophy;Vascular Parkinsonism;Dementia With Lewy Bodies | Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj;Other: Placebo | California Pacific Medical Center Research Institute | National Institute on Aging (NIA);University of California, San Francisco;Duke University;University of Pittsburgh;Parkinson's Foundation | Recruiting | 60 Years | N/A | All | 3500 | Phase 4 | United States |
| 17 | NCT04184063 (ClinicalTrials.gov) | September 16, 2019 | 29/7/2019 | Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) | A Pilot Exploratory, Randomised, Placebo-controlled, Double Blinded, Cross-over , Phase 2a Study to Explore Efficacy and Safety of NBMI Treatment in Patients With Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA) | Progressive Supranuclear Palsy;Multiple System Atrophy | Drug: NBMI;Other: Placebo | EmeraMed | NULL | Completed | 40 Years | 85 Years | All | 20 | Phase 2 | Slovenia |
| 18 | EUCTR2017-001590-16-DE (EUCTR) | 02/07/2019 | 11/01/2019 | An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) | An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) | Progressive Supranuclear Palsy (PSP) MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: ABBV-8E12 Other descriptive name: ABBV-8E12 Product Code: ABBV-8E12 Other descriptive name: ABBV-8E12 | AbbVie Deutschland | NULL | Not Recruiting | Female: yes Male: yes | 330 | Phase 2 | United States;Canada;Australia;Germany | ||
| 19 | NCT03926702 (ClinicalTrials.gov) | June 18, 2019 | 22/4/2019 | Tau Imaging With JNJ067 | Tau Imaging With JNJ067 | Alzheimer Disease;Mild Cognitive Impairment;Progressive Supranuclear Palsy | Drug: Radiopharmaceuticals | University of California, Berkeley | University of California, San Francisco | Completed | 50 Years | N/A | All | 18 | Early Phase 1 | United States |
| 20 | JPRN-UMIN000036952 | 2019/06/04 | 04/06/2019 | A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. | A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. - A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. | Patients who are suspected Parkinson's disease or related disorders, including dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobe degeneration, vascular parkinsonism, drug-induced parkinsonism, normal pressure hydrocephalus, and others. | 18F-FDOPA, 11C-Raclopride PET | Nagoya City Rehabilitation Agency | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 150 | Not applicable | Japan |
| 21 | NCT04014387 (ClinicalTrials.gov) | June 2, 2019 | 11/4/2019 | Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP) | Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP) | Treatment | Drug: Suvorexant;Drug: Zolpidem;Drug: Placebo oral capsule | University of California, San Francisco | US Department of Veterans Affairs | Recruiting | 18 Years | N/A | All | 60 | Phase 4 | United States |
| 22 | JPRN-UMIN000036908 | 2019/05/31 | 31/05/2019 | A dementia study by 11C-PiB, 18F-FDG PET | A dementia study by 11C-PiB, 18F-FDG PET - A dementia study by 11C-PiB, 18F-FDG PET | mild cognitive impairment, Alzheimer's disease, dementia with Lewy bodies, cerebrovascular dementia, frontotemporal degeneration, progressive supranuclear palsy, corticobasal degeneration, Parkinson's disease with dementia, other neurodegenerative diseases, normal pressure hydrocephalus, hypoxic encephalopathy, brain tumor, brain injury etc. | 11C-PiB, 18F-FDG PET | Nagoya City Rehabilitation Agency | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 150 | Not applicable | Japan |
| 23 | ChiCTR2000030512 | 2019-05-13 | 2020-03-05 | Clinical study of [18F]-APN-1607([18F]-PM-PBB3) PET on tau tangles in the brain of progressive supranuclear palsy | Clinical study of [18F]-APN-1607([18F]-PM-PBB3) PET on tau tangles in the brain of progressive supranuclear palsy | progressive supranuclear palsy | Gold Standard:clinical diagnosis of progressive supranuclear palsy the movement disorder society criteria in 2017.(Mov Disord. 2017 Jun;32(6):853-864. doi: 10.1002/mds.26987. Epub 2017 May 3.).;Index test:Standard uptake value ratio of [18F]-APN-1607([18F]-PM-PBB3); | Huashan Hospital, Fudan University | NULL | Recruiting | 45 | 80 | Both | Target condition:26;Difficult condition:0 | China | |
| 24 | JPRN-UMIN000036522 | 2019/04/15 | 16/04/2019 | Investigator-initiated clinical trial for progressive supranuclear palsy using an anti-cholinergic drug | Investigator-initiated clinical trial for progressive supranuclear palsy using an anti-cholinergic drug - Clinical trial for PSP using anticholinergic drug | Progressive supranuclear palsy | Trihexyphenidyl hydrochloride max.3mg for 3 months Placebo max. 3mg for 3 months | 1) Department of Neurology, Gifu University Graduate School of Medicine, 2) National Hospital Organization, Higashi Nagoya Hospital | NULL | Recruiting | 40years-old | Not applicable | Male and Female | 32 | Not selected | Japan |
| 25 | JPRN-jRCTs051180214 | 12/04/2019 | 27/03/2019 | The usefulness of flutemetamol for diagnostic imaging of neurogenerative disease | The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease - The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease | Alzheimer's disease,Dementia with Lewy Bodies,Parkinson's syndrome,Frontotemporal lober degeneration Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's syndrome, Frontotemporal lober degeneration, Parkinson's disease, Mild cognitive impairment, Non-Alzheimer's disease, Progressive aphasia, Neurodegenerative disease, Cerebral corticobasal degeneration, Progressive supranuclear palsy | Amyloid PET: Given the flutemetamol (3mL) intravenously FDG-PET:Given the FDG scanR (3mL) intravenously | Itoh Yoshiaki | NULL | Recruiting | >= 20age old | Not applicable | Both | 100 | N/A | Japan |
| 26 | EUCTR2018-000506-34-SI (EUCTR) | 04/02/2019 | 09/03/2018 | EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA). - EMERA006 | EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA). - EMERA006 | PSP or MSA;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: NBMI Product Code: NBMI INN or Proposed INN: emeramide Other descriptive name: N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE | NBMI Science Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 20 | Phase 2 | Slovenia | ||
| 27 | NCT04786158 (ClinicalTrials.gov) | December 1, 2018 | 3/3/2021 | Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA) | Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA) | Progressive Supranuclear Palsy;Corticobasal Degeneration | Drug: Apomorphine | Fondation Ophtalmologique Adolphe de Rothschild | NULL | Completed | 18 Years | N/A | All | 7 | France | |
| 28 | EUCTR2016-001635-12-ES (EUCTR) | 04/07/2018 | 10/05/2018 | A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy. | A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy | Progressive Supranuclear Palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: ABBV-8E12 INN or Proposed INN: ABBV-8E12 Other descriptive name: ABBV-8E12 Product Code: ABBV-8E12 INN or Proposed INN: ABBV-8E12 Other descriptive name: ABBV-8E12 | AbbVie Deutschland GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: yes | 330 | Phase 2 | United States;Canada;Spain;Australia;Germany;Italy | ||
| 29 | EUCTR2017-001590-16-IT (EUCTR) | 27/04/2018 | 04/11/2020 | An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) | An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) - na | Progressive Supranuclear Palsy (PSP) MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: na Product Code: ABBV-8E12 INN or Proposed INN: ABBV-8E12 | ABBVIE DEUTSCHLAND GMBH & CO. KG | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Canada;Australia;Germany;Italy | ||
| 30 | NCT03413319 (ClinicalTrials.gov) | April 17, 2018 | 23/1/2018 | Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 | Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 | Progressive Supranuclear Palsy (PSP) | Drug: ABBV-8E12 | AbbVie | NULL | Completed | 18 Years | N/A | All | 3 | Phase 1 | United States |
| 31 | NCT03545789 (ClinicalTrials.gov) | March 12, 2018 | 15/3/2018 | Phase 1 Test-retest Evaluation of [18F]MNI-958 PET | Phase 1 Test-retest Evaluation of [18F]MNI-958 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease and Probable PSP as Compared to Healthy Volunteers | Healthy Volunteers;Alzheimer Disease;Progressive Supranuclear Palsy | Drug: [18F]MNI-958 | Invicro | NULL | Completed | 18 Years | 55 Years | All | 16 | Phase 1 | United States |
| 32 | EUCTR2016-002554-21-GR (EUCTR) | 09/03/2018 | 02/01/2018 | Study of BIIB092 in Participants With Progressive Supranuclear Palsy | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy | Progressive supranuclear palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: BIIB092 INN or Proposed INN: BIIB092 Other descriptive name: BIIB092 | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 396 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Japan;Korea, Republic of | ||
| 33 | EUCTR2016-002554-21-IT (EUCTR) | 24/01/2018 | 25/05/2021 | A study to test the effectiveness and safety of test product BIIB092 compared to placebo in participants with progressive supranuclear palsy, arare and progressive condition that can cause problems with balance, movement, vision, speech and swallowing | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy - A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and s | Progressive supranuclear palsy MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BIIB092 Product Code: [BIIB092] INN or Proposed INN: BIIB092 | BIOGEN IDEC RESEARCH LIMITED | NULL | Not Recruiting | Female: yes Male: yes | 459 | Phase 2 | United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Netherlands;Japan;Korea, Republic of | ||
| 34 | NCT03391765 (ClinicalTrials.gov) | January 24, 2018 | 2/1/2018 | An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) | An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) | Progressive Supranuclear Palsy (PSP) | Drug: ABBV-8E12;Drug: Placebo solution for IV infusion on Day 15 | AbbVie | NULL | Terminated | 40 Years | N/A | All | 142 | Phase 2 | United States;Australia;Canada;Italy;Japan;France |
| 35 | NCT03625128 (ClinicalTrials.gov) | January 2, 2018 | 12/7/2018 | 18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls | Phase 0 Evaluation of Clinical and Neuroimage (18F-PM-PBB3 PET) Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls | Alzheimer's Disease;Cortical Basal Syndrome;Frontotemporal Dementia;Progressive Supranuclear Palsy;Vascular Cognitive Impairment | Drug: F-18 | Chang Gung Memorial Hospital | NULL | Completed | 20 Years | 90 Years | All | 36 | Early Phase 1 | Taiwan |
| 36 | EUCTR2016-001635-12-DE (EUCTR) | 23/11/2017 | 20/02/2017 | A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy. | A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy | Progressive Supranuclear Palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: ABBV-8E12 Product Code: ABBV-8E12 Other descriptive name: ABBV-8E12 | AbbVie Deutschland GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: yes | 330 | Phase 2 | United States;Canada;Spain;Australia;Germany;Italy | ||
| 37 | EUCTR2016-001635-12-FR (EUCTR) | 26/10/2017 | 17/07/2017 | A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy. | A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy | Progressive Supranuclear Palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: ABBV-8E12 | AbbVie Deutschland GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | Canada;United States;Italy;France;Australia;Germany;Spain | ||
| 38 | EUCTR2016-002554-21-DE (EUCTR) | 18/08/2017 | 19/04/2017 | A study of BIIB092 in participants with Progressive Supranuclear Palsy | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB0092 in Participants with Progressive Supranuclear Palsy | Progressive supranuclear palsy MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: BIIB092 INN or Proposed INN: BIIB092 Other descriptive name: BIIB092 | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 459 | Phase 2 | United States;Greece;Spain;Austria;Russian Federation;Italy;United Kingdom;France;Canada;Australia;Germany;Japan;Korea, Republic of | ||
| 39 | JPRN-JapicCTI-173627 | 01/8/2017 | 26/06/2017 | Study of BMS-986168 in Patients With Progressive Supranuclear Palsy (PASSPORT) | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Intervention name : BMS-986168 Dosage And administration of the intervention : BMS-986168 intravenous infusion on specified days Control intervention name : Placebo Dosage And administration of the control intervention : Placebo intravenous infusion on specified days | Bristol-Myers Squibb K.K. | NULL | 41 | 86 | BOTH | 396 | Phase 2 | NULL | |
| 40 | EUCTR2016-002554-21-GB (EUCTR) | 21/07/2017 | 10/04/2017 | Study of BIIB092 in Participants With Progressive Supranuclear Palsy | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy | Progressive supranuclear palsy MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: BIIB092 INN or Proposed INN: BIIB092 Other descriptive name: BIIB092 | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 459 | Phase 2 | Canada;Australia;Germany;Japan;Korea, Republic of;United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France | ||
| 41 | EUCTR2016-002554-21-AT (EUCTR) | 30/06/2017 | 20/04/2017 | Study of BIIB092 in Participants With Progressive Supranuclear Palsy | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy | Progressive supranuclear palsy MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: BIIB092 INN or Proposed INN: BIIB092 Other descriptive name: BIIB092 | Biogen Idec Research Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 459 | Phase 2 | United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Japan;Korea, Republic of | ||
| 42 | EUCTR2016-002554-21-ES (EUCTR) | 08/06/2017 | 24/04/2017 | A study to test the effectiveness and safety of test product BMS-986168 compared to placebo in participants with progressive supranuclear palsy, a rare and progressive condition that can cause problems with balance, movement, vision, speech and swallowing | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy | Progressive supranuclear palsy MedDRA version: 19.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: BMS-986168 INN or Proposed INN: BMS986168 Other descriptive name: BMS986168 | Bristol-Myers Squibb International Corporation | NULL | Not Recruiting | Female: yes Male: yes | 396 | Phase 2 | United States;Greece;Spain;Austria;Russian Federation;Italy;United Kingdom;France;Canada;Australia;Germany;Netherlands;Japan;Korea, Republic of | ||
| 43 | NCT03068468 (ClinicalTrials.gov) | June 1, 2017 | 27/2/2017 | Study of BIIB092 in Participants With Progressive Supranuclear Palsy | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy | Supranuclear Palsy, Progressive | Drug: BIIB092;Drug: Placebo | Biogen | NULL | Terminated | 41 Years | 86 Years | All | 490 | Phase 2 | United States;Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom |
| 44 | EUCTR2016-001635-12-IT (EUCTR) | 31/05/2017 | 05/02/2018 | A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy. | A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy - NA | Progressive Supranuclear Palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: ABBV-8E12 Product Code: ABBV-8E12 INN or Proposed INN: ABBV-8E12 | ABBVIE DEUTSCHLAND GMBH & CO. KG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 180 | Phase 2 | United States;Canada;Australia;Italy | ||
| 45 | EUCTR2017-000094-36-SE (EUCTR) | 31/03/2017 | 30/01/2017 | The BioFINDER 2 study - improved diagnostics and increased understanding of the underlying mechanisms of cognitive disorders | The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders | Neurodegenerative disorders with Tau-pathology; including, but not limited to, Alzheimers disease, progressive supranuclear palsy,frontotemporal dementia, corticobasal degeneration and mild cognitive impairment. MedDRA version: 19.1;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1;Classification code 10012267;Term: Dementia;Classification code 10067889;Term: Dementia with Lewy bodies;Level: HLGT;Classification code 10028037;Term: Movement disorders (incl parkinsonism);Classification code 10012271;Term: Dementia Alzheimer's type;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes);Level: LLT;Classification code 10009846;Term: Cognitive impairment;Classification code 10048598;Term: Cognitive disorders;Classification code 10001896;Term: Alzheimer's disease;Classification code 10012285;Term: Dementia due to Pick's disease;Classification code 10036813;Term: Progressive supranuclear palsy;Classification code 10074616;Term: Prodromal Alzheimer's;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | Product Name: 18F-RO6958948 Trade Name: Vizamyl (flutemetamol(F-18)) Product Name: Vizamyl | Skåne University Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2 | Sweden | |||
| 46 | NCT02985879 (ClinicalTrials.gov) | December 12, 2016 | 1/12/2016 | A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP) | A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Placebo;Drug: ABBV-8E12 | AbbVie | NULL | Terminated | 40 Years | N/A | All | 378 | Phase 2 | United States;Australia;Canada;France;Germany;Italy;Japan;Spain |
| 47 | NCT03058965 (ClinicalTrials.gov) | November 29, 2016 | 12/1/2017 | Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain | Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease or Progressive Supranuclear Palsy Compared With Healthy Volunteers | Alzheimer Disease;Healthy Volunteers;Progressive Supranuclear Palsy | Drug: [18F]MNI-958;Drug: [18F]Florbetapir;Drug: DaTscan | Molecular NeuroImaging | NULL | Completed | 50 Years | 90 Years | All | 12 | Early Phase 1 | United States |
| 48 | NCT03080051 (ClinicalTrials.gov) | August 2016 | 12/1/2017 | Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain | Phase 0 Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Progressive Supranuclear Palsy or Alzheimer's Disease Compared to Healthy Volunteers | Progressive Supranuclear Palsy;Alzheimer Disease;Healthy Volunteers | Drug: [18F]MNI-952;Drug: [18F]Florbetapir | Molecular NeuroImaging | NULL | Completed | 18 Years | 90 Years | All | 6 | Early Phase 1 | United States |
| 49 | NCT02994719 (ClinicalTrials.gov) | March 1, 2016 | 21/12/2015 | Gait Analysis in Neurological Disease | Gait Pattern Analysis in Neurological Disease | Parkinson's Disease;Parkinsonian Disorders;Atypical Parkinson Disease;Progressive Supranuclear Palsy;Multiple System Atrophy;Corticobasal Degeneration;Gait, Frontal;Huntington Disease | Drug: Anti-Parkinson medication;Device: Deep Brain Stimulation | Beth Israel Deaconess Medical Center | NULL | Active, not recruiting | 18 Years | 85 Years | All | 120 | United States | |
| 50 | NCT02658916 (ClinicalTrials.gov) | February 22, 2016 | 13/1/2016 | Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 | A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003 | Supranuclear Palsy, Progressive | Drug: BIIB092 | Biogen | NULL | Terminated | 41 Years | 86 Years | All | 47 | Phase 1 | United States |
| 51 | NCT02605785 (ClinicalTrials.gov) | November 2015 | 3/11/2015 | A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy | A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: F-18 AV 1451 | Mayo Clinic | NULL | Recruiting | 35 Years | N/A | All | 332 | N/A | United States |
| 52 | NCT02460094 (ClinicalTrials.gov) | October 2, 2015 | 20/5/2015 | Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy | A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: BIIB092;Drug: Placebo | Biogen | NULL | Completed | 41 Years | 86 Years | All | 48 | Phase 1 | United States |
| 53 | NCT02494024 (ClinicalTrials.gov) | July 2015 | 30/6/2015 | Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy | A Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Single dose C2N-8E12;Drug: Single dose placebo | C2N Diagnostics | NULL | Completed | 50 Years | 85 Years | All | 32 | Phase 1 | United States |
| 54 | NCT02460731 (ClinicalTrials.gov) | May 2015 | 19/5/2015 | Young Plasma Transfusions for Progressive Supranuclear Palsy | A 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Biological: Fresh Frozen Plasma | University of California, San Francisco | NULL | Completed | 50 Years | 85 Years | All | 6 | Phase 1 | United States |
| 55 | NCT02531360 (ClinicalTrials.gov) | May 2015 | 9/6/2015 | Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies | Phase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other Tauopathies | Alzheimer's Disease (AD);Progressive Supranuclear Palsy (PSP);Cortical Basal Syndrome (CBS);Frontal Temporal Dementia (FTD) | Drug: [18F]MNI-815 (MNI-815) | Molecular NeuroImaging | Piramal Imaging SA | Completed | 50 Years | 90 Years | Both | 7 | Phase 0 | United States |
| 56 | NCT02422485 (ClinicalTrials.gov) | April 2015 | 9/4/2015 | A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy | A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Salsalate | Adam Boxer | NULL | Completed | 50 Years | 85 Years | All | 10 | Phase 1 | United States |
| 57 | EUCTR2013-003740-23-ES (EUCTR) | 04/02/2015 | 05/12/2013 | Evaluation of masitinib in the treatment of Progressive Supranuclear Palsy | A prospective, multicentre, randomised, double-blind, placebo-controlled, parallel groups, phase 2b/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Progressive Supranuclear Palsy (PSP) | Progressive Supranuclear Palsy MedDRA version: 14.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: masitinib 100mg Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: MASITINIB MESYLATE Product Name: masitinib 200mg Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: MASITINIB MESYLATE | AB Science | NULL | Not Recruiting | Female: yes Male: yes | 90 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | Spain | ||
| 58 | EUCTR2014-000422-38-SE (EUCTR) | 19/09/2014 | 05/08/2014 | A study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of the protein tau | An open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau | Neurodegenerative disorders with Tau-pathology; including Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and important differential diagnostic conditions. MedDRA version: 17.0;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes);System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.0;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;Level: LLT;Classification code 10009846;Term: Cognitive impairment;Classification code 10001896;Term: Alzheimer's disease;Classification code 10012285;Term: Dementia due to Pick's disease;Classification code 10012267;Term: Dementia;Classification code 10067889;Term: Dementia with Lewy bodies;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | Product Name: 18F-AV-1451 | Skåne University Hospital, Region Skåne | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Sweden | ||||
| 59 | NCT02167594 (ClinicalTrials.gov) | August 12, 2014 | 17/6/2014 | Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers | 18F-AV-1451 Injection for Brain Imaging of Tau in Subjects With Progressive Supranuclear Palsy (PSP), Subjects With Corticobasal Degeneration (CBD) and Healthy Volunteers | Progressive Supranuclear Palsy;Corticobasal Degeneration | Drug: Flortaucipir F18;Procedure: Brain PET scan | Avid Radiopharmaceuticals | NULL | Completed | 50 Years | 85 Years | All | 29 | Phase 1 | United States |
| 60 | NCT02133846 (ClinicalTrials.gov) | May 2014 | 6/5/2014 | Safety Study of TPI-287 to Treat CBS and PSP | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy | Primary Four Repeat Tauopathies (4RT);Corticobasal Syndrome (CBS);Progressive Supranuclear Palsy (PSP);Corticobasal Degeneration (CBD) | Drug: TPI 287 2 mg/m2;Drug: TPI-287 20 mg/m2;Drug: Placebo;Drug: TPI-287 6.3 mg/m2 | University of California, San Francisco | CBD Solutions;Tau Consortium | Completed | 50 Years | 85 Years | All | 44 | Phase 1 | United States |
| 61 | EUCTR2012-005539-10-DE (EUCTR) | 29/04/2014 | 18/12/2013 | Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions. | Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two dose levels of NT 201 in treating chronic troublesome sialorrhea in various neurological conditions - SIAXI – Sialorrhea in Adults Xeomin Investigation | Chronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive supranuclear palsy), or after stroke or traumatic brain injury. MedDRA version: 18.1;Level: PT;Classification code 10039424;Term: Salivary hypersecretion;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Xeomin INN or Proposed INN: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A Trade Name: Xeomin INN or Proposed INN: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A | Merz Pharmaceuticals GmbH | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 3 | United States;Poland;Germany | ||
| 62 | NCT02103894 (ClinicalTrials.gov) | February 2014 | 12/2/2014 | Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects | Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects | Alzheimer's Disease (AD);Parkinson's Disease (PD);Chronic Traumatic Encephalopathy (CTE);Progressive Supranuclear Palsy (PSP);Frontal Temporal Dementia (FTD);Pick's Disease;Tauopathies | Drug: [18F]T807 ([18F]MNI-777) | Molecular NeuroImaging | Institute for Neurodegenerative Disorders | Completed | 18 Years | 85 Years | Both | 16 | Phase 1 | United States |
| 63 | NCT02214862 (ClinicalTrials.gov) | March 2013 | 11/8/2014 | 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism | Pilot, Exploratory Study With [F18]-FDDNP-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism | Progressive Supranuclear Palsy;Multi-System Atrophy;Parkinsonism | Drug: [F18]-FDDNP | Fundacion Clinic per a la Recerca Biomédica | NULL | Completed | 40 Years | N/A | Both | 40 | Phase 0 | Spain |
| 64 | NCT01824121 (ClinicalTrials.gov) | December 2012 | 31/3/2013 | Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism | Autologous Mesenchymal Stem Cell Therapy in Progressive Supranuclear Palsy: a Randomized, Double-blind, Controlled Clinical Trial | Progressive Supranuclear Palsy | Biological: stem cell therapy | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | NULL | Recruiting | 40 Years | N/A | Both | 25 | Phase 1/Phase 2 | Italy |
| 65 | JPRN-UMIN000008959 | 2012/11/01 | 16/10/2012 | Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsy | Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsy - Randomized Double-blind, Placebo-controlled trial on molecular hydrogen water in MSA and PSP | Multiple system atrophy(MSA)Progressive supranuclear palsy (PSP) | hydrogen water pseudo-water (nitrogen filling water) | Juntendo University School of Medicine, Department of Neurology | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 40 | Phase 1 | Japan |
| 66 | EUCTR2010-019159-23-GB (EUCTR) | 22/12/2010 | 08/10/2010 | A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. | A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. | Progressive Supranuclear Palsy MedDRA version: 14.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Davunetide Product Code: AL-108 INN or Proposed INN: Davunetide | Allon Therapeutics Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | France;United States;Canada;Australia;Germany;United Kingdom | ||
| 67 | EUCTR2010-019159-23-DE (EUCTR) | 08/11/2010 | 27/08/2010 | A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. | A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. | Progressive Supranuclear Palsy MedDRA version: 14.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Davunetide Product Code: AL-108 INN or Proposed INN: Davunetide | Allon Therapeutics Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2/3 | France;United States;Canada;Australia;Germany;United Kingdom | ||
| 68 | NCT01110720 (ClinicalTrials.gov) | October 2010 | 23/4/2010 | Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Davunetide;Drug: Placebo | Allon Therapeutics | NULL | Completed | 41 Years | 85 Years | Both | 313 | Phase 2/Phase 3 | United States;Australia;Canada;France;Germany;United Kingdom |
| 69 | NCT01537549 (ClinicalTrials.gov) | September 14, 2010 | 9/1/2012 | Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy | An Open-label Trial of Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy (PSP): Effect Upon Oxidative Damage and Mitochondrial Biomarkers | Progressive Supranuclear Palsy | Drug: alpha-lipoic acid and L-acetyl carnitine | Weill Medical College of Cornell University | NULL | Completed | 40 Years | 75 Years | All | 11 | Phase 1/Phase 2 | United States |
| 70 | EUCTR2008-007520-26-DE (EUCTR) | 24/06/2010 | 13/11/2009 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III) | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III) | Progressive Supranuclear Palsy MedDRA version: 12.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy | Trade Name: Azilect INN or Proposed INN: Rasagilin Other descriptive name: RASAGILINE MESILATE | Klinikum der Universität München | NULL | Not Recruiting | Female: yes Male: yes | Phase 3 | Germany | |||
| 71 | NCT01056965 (ClinicalTrials.gov) | January 2010 | 21/1/2010 | Davunetide (AL-108) in Predicted Tauopathies - Pilot Study | A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies | Predicted Tauopathies, Including;Progressive Supranuclear Palsy;Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17;Corticobasal Degeneration Syndrome;Progressive Nonfluent Aphasia | Drug: davunetide (AL-108, NAP);Drug: Placebo nasal spray | University of California, San Francisco | NULL | Completed | 40 Years | 85 Years | All | 12 | Phase 1 | United States |
| 72 | NCT01187888 (ClinicalTrials.gov) | January 2010 | 20/8/2010 | Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Rasagiline in Subjects With Progressive Supranuclear Palsy (Phase III) | Progressive Supranuclear Palsy | Drug: Rasagiline;Drug: Sugar pill | Prof. Dr. Stefan Lorenzl | Teva Pharmaceutical Industries;Ludwig-Maximilians - University of Munich | Terminated | 50 Years | 80 Years | Both | 44 | Phase 3 | Germany |
| 73 | NCT01049399 (ClinicalTrials.gov) | December 2009 | 13/1/2010 | Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy | A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112, a GSK-3 Inhibitor, Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: tideglusib;Drug: placebo | Noscira SA | i3 Research | Completed | 40 Years | 85 Years | Both | 146 | N/A | United States;Germany;Spain;United Kingdom |
| 74 | EUCTR2009-013097-40-ES (EUCTR) | 17/11/2009 | 29/07/2009 | Estudio doble-ciego, controlado con placebo, aleatorizado, de grupos paralelos, para evaluar la seguridad, tolerancia y eficacia de dos dosis orales diferentes de NP031112, un inhibidor de GSK3, versus placebo, como tratamiento de pacientes con Parálisis Supranuclear Progresiva leve o moderada | Estudio doble-ciego, controlado con placebo, aleatorizado, de grupos paralelos, para evaluar la seguridad, tolerancia y eficacia de dos dosis orales diferentes de NP031112, un inhibidor de GSK3, versus placebo, como tratamiento de pacientes con Parálisis Supranuclear Progresiva leve o moderada | Parálisis Supranuclear Progresiva leve o moderada MedDRA version: 9;Level: LLT;Classification code 10036813;Term: Progressive supranuclear palsy MedDRA version: 9;Level: PT;Term: Progressive supranuclear palsy | Product Name: NP031112 Product Code: NP031112 600mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione Product Name: NP031112 Product Code: NP031112 800mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | Noscira S.A. | NULL | Not Recruiting | Female: yes Male: yes | 125 | Spain;Germany;United Kingdom | |||
| 75 | EUCTR2009-013097-40-DE (EUCTR) | 06/11/2009 | 30/07/2009 | A double-blind, placebo-controlled, randomized, parallel-group study evaluating thesafety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3inhibitor, versus placebo in the treatment of patients with mild to moderateProgressive Supranuclear Palsy. - TAUROS | A double-blind, placebo-controlled, randomized, parallel-group study evaluating thesafety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3inhibitor, versus placebo in the treatment of patients with mild to moderateProgressive Supranuclear Palsy. - TAUROS | Mild to Moderate Progressive Supranuclear Palsy MedDRA version: 12.0;Level: LLT;Classification code 10036813;Term: Progressive supranuclear palsy MedDRA version: 12.0;Level: PT;Term: Progressive supranuclear palsy | Product Name: NP031112 Product Code: NP031112 600mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione Product Name: NP031112 Product Code: NP031112 800mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | Noscira S.A. | NULL | Not Recruiting | Female: yes Male: yes | 125 | United Kingdom;Spain;Germany | |||
| 76 | EUCTR2009-013097-40-GB (EUCTR) | 30/10/2009 | 23/07/2009 | A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the treatment of patients with mild to moderate Progressive Supranuclear Palsy. - TAUROS | A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the treatment of patients with mild to moderate Progressive Supranuclear Palsy. - TAUROS | Mild to Moderate Progressive Supranuclear Palsy MedDRA version: 12.0;Level: LLT;Classification code 10036813;Term: Progressive supranuclear palsy MedDRA version: 12.0;Level: PT;Term: Progressive supranuclear palsy | Product Name: NP031112 Product Code: NP031112 600mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione Product Name: NP031112 Product Code: NP031112 800mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | Noscira S.A. | NULL | Not Recruiting | Female: yes Male: yes | 140 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Spain;Germany;United Kingdom | ||
| 77 | NCT00703677 (ClinicalTrials.gov) | September 2008 | 20/6/2008 | A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration | A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration | Progressive Supranuclear Palsy;Corticobasal Degeneration | Drug: Lithium | Westat | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | 40 Years | 80 Years | All | 17 | Phase 1/Phase 2 | United States;United Kingdom |
| 78 | NCT00522015 (ClinicalTrials.gov) | February 2008 | 27/8/2007 | Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy | Rivastigmine (Exelon®) for Treatment of Dementia in Patient With Progressive Supranuclear Paresis Open Label Phase 2 Study | Progressive Supranuclear Palsy;Dementia | Drug: rivastigmine | University Hospital Tuebingen | NULL | Recruiting | 50 Years | N/A | Both | 20 | Phase 2 | Germany |
| 79 | EUCTR2006-006166-42-DE (EUCTR) | 17/07/2007 | 02/01/2007 | Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -offene, prospektive Phase II-Studie - | Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -offene, prospektive Phase II-Studie - | Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with hardly any therapeutical option to ameliorate the course of the disease. Results of first trials with physostigmine and donepezil did not point out a definite benefit. In contrast, first clinical observations concerning an effect with rivastigmine in PSP with dementia were promising. This may be due to the fact, that rivastigmine excerts a double action inhibiting both the acetylcholin- and the buturylcholinesterase. | Trade Name: Exelon 1,5 mg Hartkapseln INN or Proposed INN: RIVASTIGMINE Trade Name: Exelon 3,0 mg Hartkapseln INN or Proposed INN: RIVASTIGMINE Trade Name: Exelon 6,0 mg Hartkapseln INN or Proposed INN: RIVASTIGMINE | University of Tuebingen | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2 | Germany | |||
| 80 | NCT00385710 (ClinicalTrials.gov) | November 2006 | 10/10/2006 | Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine) | Randomized Placebo-controlled Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: valproic acid;Drug: Placebo | Nantes University Hospital | NULL | Completed | 45 Years | 75 Years | Both | 28 | Phase 2 | France |
| 81 | NCT00382824 (ClinicalTrials.gov) | September 2006 | 28/9/2006 | Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) | Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP): A Multicenter, Randomized, Placebo-controlled, Double Blind Study | Progressive Supranuclear Palsy | Dietary Supplement: Coenzyme Q10;Other: Placebo | Lahey Clinic | NULL | Completed | 30 Years | N/A | All | 61 | N/A | United States |
| 82 | NCT00328874 (ClinicalTrials.gov) | May 2006 | 21/5/2006 | Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy | Mono-center, Prospective, Double-blind, Placebo-controlled, Randomized Clinical Phase IIa Trial to Assess the Safety, Tolerability, and Immediate Biological Effects of Coenzyme Q10 - nanoQuinon® in Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Coenzyme Q10 | German Parkinson Study Group (GPS) | MSE Pharmazeutika GmbH, Louisenstr.114D-61348 Bad Homburg, Germany;Pitzer Stiftung;Philipps University Marburg Medical Center | Completed | 40 Years | 85 Years | All | 20 | Phase 2 | Germany |
| 83 | EUCTR2005-000574-40-DE (EUCTR) | 24/04/2006 | 24/01/2006 | Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® - N/A | Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® - N/A | PSP is a sporadic neurodegenerative disorder resulting in a Parkinson syndrome with postural instability, oculomotor deficits, and cognitive decline. With an average annual incidence of 5.3 / 100000 and an age-adjusted prevalence of 6.4 / 100000, PSP is as common as motor-neuron disease. The progression of PSP is rapid and the median survival after onset of symptoms is 5-10 years. Presently, there is no known effective symptomatic or neuroprotective therapy for PSP. | Product Name: Coenzym Q10 Nanodispersion Product Code: ASK Nr. 21972 INN or Proposed INN: Ubidecarenon Other descriptive name: Coenzym Q10, Ubiquinon, Ubichinon | Kompetenznetz Parkinson e.V. | NULL | Not Recruiting | Female: yes Male: yes | 30 | Germany | |||
| 84 | NCT00139373 (ClinicalTrials.gov) | May 2005 | 30/8/2005 | Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy | Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy | Supranuclear Palsy, Progressive | Drug: donepezil | Groupe Hospitalier Pitie-Salpetriere | Institut National de la Santé Et de la Recherche Médicale, France | Recruiting | 30 Years | 80 Years | Both | 16 | Phase 2 | France |
| 85 | NCT00605930 (ClinicalTrials.gov) | April 2004 | 14/1/2008 | A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy. | Energy Metabolism in Neurodegenerative Diseases: A Randomized, Double Blind, Placebo-Controlled Clinical Pilot Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy. | Progressive Supranuclear Palsy | Dietary Supplement: Pyruvate, creatine, niacinamide;Dietary Supplement: Placebo | University of Louisville | NULL | Completed | N/A | N/A | All | 20 | N/A | United States |
| 86 | NCT00532571 (ClinicalTrials.gov) | January 2004 | 18/9/2007 | Effects of Coenzyme Q10 in PSP and CBD | Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study | Progressive Supranuclear Palsy;Neurological Disorders | Drug: CoQ10 | Lahey Clinic | NULL | Completed | 40 Years | N/A | All | Phase 2/Phase 3 | United States | |
| 87 | NCT00005903 (ClinicalTrials.gov) | June 2000 | 7/6/2000 | Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy | Dose-Escalation Trial of Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor for the Treatment of PSP | Progressive Supranuclear Palsy | Drug: GDNF & Synchro Med Infusion System | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | N/A | N/A | Both | 15 | Phase 2 | United States |
| 88 | NCT00211224 (ClinicalTrials.gov) | April 2000 | 13/9/2005 | Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) | Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes) | Multiple System Atrophy;Progressive Supranuclear Palsy | Drug: Riluzole | King's College London | Assistance Publique - Hôpitaux de Paris;University of Ulm;Aventis Pharmaceuticals | Terminated | 30 Years | 80 Years | Both | 800 | Phase 3 | United Kingdom |
| 89 | EUCTR2016-002554-21-FR (EUCTR) | 15/06/2018 | A study to test the effectiveness and safety of test product BMS-986168 compared to placebo in participants with progressive supranuclear palsy, a rare and progressive condition that can cause problems with balance, movement, vision, speech and swallowing | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy | Progressive supranuclear palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: BMS-986168 INN or Proposed INN: BMS986168 Other descriptive name: BMS986168 | Bristol-Myers Squibb International Corporation | NULL | NA | Female: yes Male: yes | 396 | Phase 2 | United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Netherlands;Japan;Korea, Republic of |